Cat. No. | Species | Product Description | Structure | Purity | Feature |
---|---|---|---|---|---|
FO1-HF2H8 | Human | FITC-Labeled Human FOLR1 Protein, His Tag (MALS verified) | ![]() |
![]() ![]() |
![]() ![]() |
FO1-H52H1 | Human | Human FOLR1 Protein, His Tag (MALS verified) | ![]() |
![]() ![]() ![]() ![]() |
![]() ![]() |
FO1-H82F9 | Human | Biotinylated Human FOLR1 Protein, Fc,Avitag™ | ![]() |
![]() ![]() |
![]() ![]() |
FO1-H5253 | Human | Human FOLR1 Protein, Fc Tag (MALS verified) | ![]() |
![]() ![]() |
![]() ![]() |
FO1-H82E2 | Human | Biotinylated Human FOLR1 Protein, His,Avitag™ | ![]() |
![]() ![]() |
![]() ![]() |
FO1-C52H8 | Cynomolgus / Rhesus macaque | Cynomolgus / Rhesus macaque FOLR1 Protein, His tag | ![]() |
![]() ![]() |
![]() ![]() |
FO1-M82E9 | Mouse | Biotinylated Mouse FOLR1 Protein, His,Avitag™ | ![]() |
![]() ![]() |
![]() ![]() |
FO1-M5225 | Mouse | Mouse FOLR1 Protein, His Tag | ![]() |
![]() ![]() |
![]() ![]() |
FO1-H528b | Human | Human FOLR1 Protein, Strep Tag | ![]() |
![]() ![]() |
![]() ![]() |
Immobilized Folic Acid-BSA Conjugate at 5 μg/mL (100 μL/well) can bind Human FOLR1, His Tag (Cat. No. FO1-H52H1) with a linear range of 5-78 ng/mL (QC tested).
The purity of FITC-Labeled Human FOLR1, His Tag (Cat. No. FO1-HF2H8) was more than 90% and the molecular weight of this protein is around 40-50 kDa verified by SEC-MALS.
Immobilized Folic acid-BSA conjugate at 5 μg/mL (100 μL/well) can bind FITC-Labeled Human FOLR1, His Tag (Cat. No. FO1-HF2H8) with a linear range of 0.078-1.25 μg/mL (QC tested).
Name | Research Code | Research Phase | Company | Indications | Clinical Trials |
---|---|---|---|---|---|
GALE-302 | GALE-302; E-39; J-65 | Phase Ⅱ | Galena Biopharma | Breast cancer, Ovarian cancer | Details |
OCTR lymphocytes (Centocor) | Phase Ⅱ | Johnson & Johnson | Ovarian cancer | Details | |
MOv18 IgE (King's College London) | Phase Ⅰ | King's College London, Cancer Research UK | Cancer | Details | |
Vintafolide | MK-8109; EC-145 | Phase Ⅱ | Novartis, Merck Sharp & Dohme | Non small cell lung cancer (NSCLC) | Details |
EC-1456 | EC-1456; EC-0531 | Phase Ⅰ | Novartis | Non small cell lung cancer (NSCLC), Ovarian cancer | Details |
Mirvetuximab soravtansine | IMGN-853; M9346-Asulfo-SPDB-DM4,IMGN853; M-9346-Asulfo-SPDB-DM4 | Phase Ⅲ | ImmunoGen | Fallopian tube cancer, Endometrial cancer, Breast cancer, Solid tumours, Peritoneum cancer, Ovarian cancer | Details |
EC-0905 | EC-0905 | Preclinical | Novartis | Cancer | Details |
MORAb-202 | MORAb-202,MORAb202; MORAb 202 | Phase Ⅱ | Eisai, Morphotek | Solid tumours | Details |
OTL-38 | OTL-38; OTL-0038; Pteroyl-L-Tyr-S0456; EC-17 | Phase Ⅲ | On Target | Ovarian cancer | Details |
Epofolate | BMS-753493 | Phase Ⅱ | Bristol-Myers Squibb, Novartis | Solid tumours | Details |
Anti-CD3-anti-MOv18 monoclonal antibody | Phase Ⅱ | Centocor | Ovarian cancer | Details | |
NMI-500 | Phase Ⅰ | Nemucore Medical Innovations | Breast cancer, Ovarian cancer | Details | |
EC-0305 | EC-0305; F-0305 | Phase Ⅰ | Novartis | Solid tumours | Details |
Noscapine-folate conjugate | Phase Ⅰ | Emory University | Immune-inflammatory diseases, Solid tumours, Hematological cancer | Details | |
Farletuzumab | MORAb-003,MORAb003 | Phase Ⅲ | Morphotek | Ovarian cancer | Details |
This web search service is supported by Google Inc.